Enanta Pharmaceuticals (NASDAQ:ENTA) has been given a consensus recommendation of “Buy” by the eight brokerages that are presently covering the firm, MarketBeat Ratings reports. Four equities research analysts have rated the stock with a hold rating and two have issued a strong buy rating on the company. The average 12-month price target among analysts that have issued a report on the stock in the last year is $56.33.
ENTA has been the topic of a number of research reports. ValuEngine raised Enanta Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Thursday, March 1st. Zacks Investment Research raised Enanta Pharmaceuticals from a “hold” rating to a “buy” rating and set a $82.00 price objective on the stock in a report on Monday, February 12th. BidaskClub cut Enanta Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Saturday, February 10th. Royal Bank of Canada reissued a “hold” rating and set a $80.00 price objective on shares of Enanta Pharmaceuticals in a report on Wednesday, April 4th. Finally, JPMorgan Chase lowered Enanta Pharmaceuticals from an “overweight” rating to a “neutral” rating in a research report on Thursday, February 8th.
Shares of NASDAQ ENTA traded up $3.50 during trading hours on Thursday, reaching $89.45. 59,290 shares of the stock traded hands, compared to its average volume of 209,258. The stock has a market cap of $1,647.43, a price-to-earnings ratio of 95.70 and a beta of 1.07. Enanta Pharmaceuticals has a 52-week low of $29.46 and a 52-week high of $95.91.
In related news, Treasurer Paul J. Mellett sold 9,000 shares of the firm’s stock in a transaction that occurred on Monday, March 19th. The stock was sold at an average price of $86.48, for a total transaction of $778,320.00. Following the transaction, the treasurer now directly owns 96,458 shares in the company, valued at approximately $8,341,687.84. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. 10.56% of the stock is owned by company insiders.
A number of institutional investors and hedge funds have recently bought and sold shares of the stock. BlackRock Inc. grew its position in Enanta Pharmaceuticals by 4.3% during the 4th quarter. BlackRock Inc. now owns 2,343,593 shares of the biotechnology company’s stock worth $137,521,000 after acquiring an additional 97,054 shares during the last quarter. First Manhattan Co. grew its position in Enanta Pharmaceuticals by 14.5% during the 4th quarter. First Manhattan Co. now owns 1,084,200 shares of the biotechnology company’s stock worth $63,620,000 after acquiring an additional 137,100 shares during the last quarter. Farallon Capital Management LLC grew its position in Enanta Pharmaceuticals by 124.3% during the 4th quarter. Farallon Capital Management LLC now owns 925,000 shares of the biotechnology company’s stock worth $54,279,000 after acquiring an additional 512,667 shares during the last quarter. Renaissance Technologies LLC grew its position in shares of Enanta Pharmaceuticals by 13.3% in the 4th quarter. Renaissance Technologies LLC now owns 771,600 shares of the biotechnology company’s stock worth $45,277,000 after buying an additional 90,500 shares during the last quarter. Finally, Dimensional Fund Advisors LP grew its position in shares of Enanta Pharmaceuticals by 1.4% in the 3rd quarter. Dimensional Fund Advisors LP now owns 562,394 shares of the biotechnology company’s stock worth $26,320,000 after buying an additional 7,617 shares during the last quarter. Institutional investors and hedge funds own 73.26% of the company’s stock.
About Enanta Pharmaceuticals
Enanta Pharmaceuticals, Inc, a biotechnology company, focuses on discovering and developing small molecule drugs for the treatment of viral infections and liver diseases. The company's research and development focuses on disease targets: hepatitis B virus, non-alcoholic steatohepatitis, primary biliary cholangitis, and respiratory syncytial virus.
Receive News & Ratings for Enanta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.